CEL-SCI Corporation (CVM)

NYSEAMERICAN: CVM · IEX Real-Time Price · USD
2.35
+0.10 (4.69%)
Mar 21, 2023, 3:59 PM EDT - Market closed
4.69%
Market Cap 102.79M
Revenue (ttm) n/a
Net Income (ttm) -36.87M
Shares Out 43.74M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 61,080
Open 2.26
Previous Close 2.24
Day's Range 2.26 - 2.38
52-Week Range 1.88 - 6.14
Beta 1.71
Analysts Buy
Price Target 10.71 (+356.72%)
Earnings Date Feb 14, 2023

About CVM

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 1, 1987
Employees 43
Stock Exchange NYSEAMERICAN
Ticker Symbol CVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CVM stock is "Buy." The 12-month stock price forecast is $10.71, which is an increase of 356.72% from the latest price.

Price Target
$10.71
(356.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI's Multikine Phase 3 cancer study shows 43% survival extension.

1 week ago - Business Wire

CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.

2 weeks ago - Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corpora...

1 month ago - Business Wire

CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.

2 months ago - Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

4 months ago - Business Wire

CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO22--CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annu...

6 months ago - Business Wire

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation announces Phase 3 Multikine head and neck cancer results posted on clinicaltrials.gov.

7 months ago - Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate d...

7 months ago - Business Wire

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pi...

8 months ago - Business Wire

CEL-SCI Corporation Announces Reddit AMA with Geert Kersten

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces Reddit AMA with Geert Kersten.

8 months ago - Business Wire

CEL-SCI Corporation to Present at LD Micro Invitational

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation to Present at LD Micro Invitational.

10 months ago - Business Wire

CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ASCO22--CEL-SCI presents Phase 3 Multikine head and neck cancer data at ASCO.

10 months ago - Business Wire

CEL-SCI Announces Publication of ASCO 2022 Abstracts

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces publication of ASCO 2022 abstracts.

10 months ago - Business Wire

CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation reports second quarter fiscal 2022 financial results.

11 months ago - Business Wire

CEL-SCI Announces Acceptance of Abstracts to ASCO 2022

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces acceptance of abstracts to ASCO 2022.

11 months ago - Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports first quarter fiscal 2022 financial results.

1 year ago - Business Wire

CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2021 financial results and clinical & corporate developments.

1 year ago - Business Wire

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation completes commercial-scale buildout of Multikine manufacturing facility.

1 year ago - Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.

1 year ago - Business Wire

Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.

1 year ago - Business Wire

Why CEL-SCI Shares Are Getting Hammered Today

CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in grou...

1 year ago - Benzinga

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

1 year ago - Business Wire

CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today

Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appea...

1 year ago - InvestorPlace

CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients

CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In ...

1 year ago - Benzinga